In the press
Wall Street Journal
Wall Street Journal
The following was taken from the Wall Street Journal. Check out the original piece here: https://www.wsj.com/articles/vc-daily-biotechs-test-new-company-building-model-11614261635
We are incredibly excited and humbled to be recognized in the Wall Street Journal for our innovative business model!
We thank everyone who has been supporting us from the beginning.
Related Press
Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development… Continue reading Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
IF HENRY FORD WERE IN BIOTECH
IF HENRY FORD WERE IN BIOTECH Please join us to hear from our CEO, Marc Appel.
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas.
Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area The following excerpt was taken from Cincinnati Enquirer — continue reading here. Orange Grove Bio, a venture capital firm that invests mainly in therapeutic drug companies, is moving its headquarters from the New York City “Orange Grove Bio, a venture capital firm that invests… Continue reading Cincinnati’s ‘innovation district’ lures biotech HQ from New York City area
Pre-clinical Biotech Development Opportunity Video
Pre-clinical Biotech Development Opportunity Video
Orange Grove Bio and Cincinnati Children’s Hospital Medical Center Establish Collaboration
Orange Grove Bio, a preclinical drug investment and development firm, and Cincinnati
IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform The following excerpt was taken from Trialsitenews — continue reading here. IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform “New York-based IpiNovyx Bio announced the closing of a $10 million seed financing round. The financing was led… Continue reading IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)… Continue reading Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition
Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition The following excerpt was taken from Einsteinmed.edu — continue reading here. Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend Albert Einstein College… June 27, 2022—(BRONX, NY)—Scientists, venture investment firm leaders, and industry stakeholders gathered on Tuesday, June 7 to attend… Continue reading Einstein Hosts Inaugural Therapeutics Venture and Pitch Competition